Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab Prolongs OS Among Patients with Early-Stage TNBC By Ogkologos - November 8, 2024 670 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the KEYNOTE-522 study Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR Junk food marketing restrictions: so near and yet so far December 15, 2022 Immunotherapy’s Role in Treating Endometrial Cancer Expected to Grow April 12, 2023 Study Identifies Potential Warning Signs of Colorectal Cancer in Younger Adults June 15, 2023 Test Detects Early Signs of Remaining Cancer in Kids Treated for... December 8, 2021 Load more HOT NEWS How Early Cancer Detection and Diagnosis Saved My Life Twice: A... Surveillance and Early Cancer Detection are Associated with Improved Survival in... 3-Year-Old Boy Receives Hundreds Of Sweet Birthday Cards In The Mail... Investigating suspected prostate cancer: improving GP-patient communication
